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The efficacy and safety of statin therapy are well established. However, despite their favourable profile, muscle symptoms reported with statin therapy limit their use negatively impacting adherence and cardiovascular benefits of this treatment. It is important that clinicians are cautious before attributing muscle symptoms to statin therapy, without further investigation of their cause. Moreover, this is complicated by the lack of internationally agreed clinical definitions of statin-induced myopathy and diagnostic tools.
Recently the European Atherosclerosis Society (EAS) Consensus Panel has circumvented the lack of consensus regarding the causality of statins with muscle symptoms by the use of the term statin-associated muscle symptoms, Table 1 Definition of statin-associated muscle symptoms from reference (Table 1) , thus providing an accessible resource for the diagnosis, assessment, and management of SAMS, as well as an update on current thinking about the aetiology of statin myopathy.
Understanding and clearly defining is critical for optimal treatment. Therefore, the management of SAMS is a key in the effective treatment of patients with cardiovascular disease (CVD), through achievement of maximumtolerated statin dosing and other practical aspects. Combination therapy with ezetimibe and the addition of Proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients with elevated LDL-C is supported by a pharmacological and clinical evidence and is the logical approach to maintain patients on statin therapy with the final aim to optimize the cardiovascular benefits of this treatment.
